HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results
HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter
Homerun Resources Inc. Advances Solar Glass Project Financing with Letter of Intent from Leading European Project Finance Bank for up to 170 Million Euros
Transition Metals Commences 2026 Exploration Program at Pike Warden Epithermal Gold-Silver and Porphyry Copper Project, Yukon
Infill Drilling Significantly Widens and Extends Near Surface Gold Mineralisation at Gemdale Gold's Pontio Gold Project, Finland
SAGA Metals Reports Assays from R-0055 to R-0057 with Intercepts Including 53.72% Fe2O3, 8.24% TiO2, 0.377% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador
